Key Documents

View All Documentation

SML2142

Silodosin

Name: Silodosin
Brand: SIGMA

≥98% (HPLC), alpha 1-adrenoceptor antagonist, powder

Synonym(s):

1-(3-Hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide, Rapaflo, Rapallo, Silodyx, Urief

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₅H₃₂F₃N₃O₄

CAS Number:

160970-54-7

Molecular Weight:

495.53

NACRES:

NA.77

UNSPSC Code:

12352200

MDL number:

MFCD00930170

Assay:

≥98% (HPLC)

Form:

powder

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Product Name

Silodosin, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

NC(C1=CC(C[C@@H](C)NCCOC2=C(OCC(F)(F)F)C=CC=C2)=CC3=C1N(CCCO)CC3)=O

InChI

1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1

InChI key

PNCPYILNMDWPEY-QGZVFWFLSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecules

Biochem/physiol Actions

Selective alpha 1-adrenoceptor antagonist

Silodosin is a selective alpha 1-adrenoceptor antagonist with high affinity for the ?1A adrenergic receptor, used clinically for the treatment of benign prostatic hyperplasia (BPH).

pictograms

GHS08,GHS07

signalword

Warning

hcodes

H302,H373

pcodes

P301 + P312 + P330 - P314

Hazard Classifications

Acute Tox. 4 Oral - STOT RE 2

target_organs

Liver

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?

Claus G Roehrborn et al.

Advances in therapy, 33(12), 2110-2121 (2016-11-05)

Available α1-blockers (ABs) have different profiles of receptor selectivity. Silodosin exhibits the highest selectivity for the α

Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.

Takashi Yoshida et al.

Urology, 106, 153-159 (2017-04-23)

To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH) treated with the α We analyzed 103 patients with LUTS/BPH with

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis.

Hui Ding et al.

Renal failure, 38(9), 1311-1319 (2016-11-04)

To evaluate the efficacy of Silodosin as a medical expulsive therapy of ureteral stones, we searched PubMed, EMBASE, the Cochrane Library, and CBM up to June 2015. All randomized controlled trials (RCTs) were identified in which patients were randomized to

Global Trade Item Number

SKU	GTIN
SML2142-10MG	04061835253548
SML2142-50MG	04061835253555

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service